MeMed granted a CE mark for use of its MeMed BV diagnostic test and MeMed Key point-of-need platform

MeMed, in Europe, has earned a CE mark for the use of its MeMed BV diagnostic test and MeMed Key point-of-need platform. MeMed BV implements AI to differentiate between viral and bacterial infections after measuring host-immune response proteins from a small sample of blood, which provides information intended to inform better antiviral and antibiotic treatment choices.

Furthermore, MeMed BV has been validated by data from more than fifteen-thousand multinationals and patients, double-blind clinical studies which have been distributed in journals, conveying over ninety per cent specificity and sensitivity across several pathogens.

Co-founder and CEO of Memed, Eran Eden, stated: “At its core, MeMed is about decoding the signals of the host immune response to help physicians make better informed decisions that improve patients’ lives. The CE-IVD mark brings us closer to impacting patients around the globe. We believe MeMed BV and MeMed Key will be a major addition to the clinical arsenal, improving outcomes for patients with acute infections, lowering healthcare costs and combating antibiotic resistance. We are indebted to the United States Department of Defence and the European Commission for their continuous support, helping us reach this significant milestone, as well as to our research collaborators who are generating an unprecedented amount of clinical evidence in the US, Europe and other regions around the globe.”